Taksta

This article needs to be updated. Please help update this article to reflect recent events or newly available information. (August 2023)

|

Taksta (previously CEM-102) is a front-loaded[clarification needed] oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus.[1]

## Clinical trials[edit]

Jan 2010: Taksta has completed enrollment in a phase 2 trial (due to run until March 2010) and is preparing for phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with linezolid).[2]

Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.[3]

Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.[4]

Dec 2015: Cempra doses first patient in a phase 3 clinical trial of Taksta in acute bacterial skin and skin structure infections.[5]

Nov 2016: Cempra completes a phase 3 clinical trial of Taksta in acute bacterial skin and skin structure infections. Results remain pending.[6]

Feb 2017: Cempra achieves the primary endpoint of a 10% non-inferiority margin. The microbiological success in each ME[clarification needed] population with methicillin-resistant S. aureus infection is 100 percent (99/99) at both the EOT[clarification needed] and PTE[clarification needed] visits.[7]

## See also[edit]

* Fusidic acid, licensed for some decades outside the US and is in clinical development in the U.S.

## References[edit]

1. ^ "Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs Taksta and CEM-101".
2. ^ "Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections". 15 April 2019.
3. ^ Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). "A randomized, double-blind Phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections." Clinical Infectious Diseases 52 (Supplement 7):S520-S226.
4. ^ Wolfe CR. (2011) "Case report: treatment of chronic osteomyelitis." Clinical Infectious Diseases 52(Supplement 7):S538-S541.
5. ^ "Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta in Acute Bacterial Skin and Skin Structure Infections". investor.cempra.com. December 8, 2015. Archived from the original on August 5, 2016. Retrieved 16 April 2023.
6. ^ "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections". ClinicalTrials.gov. FDA. Retrieved 17 December 2016.
7. ^ "Cempra's Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI". Cempra.com. Cempra. Retrieved 4 April 2017.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template